The Cancer Drug That Worked But Still Got Rejected
ITM's cancer drug aced its clinical trials and proved it could help patients live longer without their tumors progressing. Then the FDA rejected it anyway, citing manufacturing problems. It's a cautionary tale for the entire radiopharmaceutical sector.
Imagine acing every exam in medical school, nailing your residency, and then being told you can't practice medicine because your handwriting on the application form was illegible. That's roughly what just happened to ITM Isotope Technologies Munich.
On August 7, 2026, the FDA issued a Complete Response Letter (CRL) for ITM-11, the company's cancer-fighting radiopharmaceutical. A CRL is the agency's formal way of saying: "We can't approve this right now." But the reason wasn't that the drug didn't work. It wasn't that patients got hurt. The FDA's issue was with manufacturing quality, not the medicine itself.
The drug cleared its clinical hurdles. The factory didn't clear its regulatory ones.
A Drug That Did Its Job
ITM-11, known technically as n.c.a. lutetium-177-edotreotide, was built for a specific and stubborn type of cancer: gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These are rare tumors that grow in the digestive system and pancreas. They're tough to treat, and patients desperately need better options.
ITM ran a Phase 3 trial called COMPETE, the gold-standard test for proving a drug works. The result? ITM-11 met its primary endpoint, showing a significant improvement in progression-free survival. In plain English, patients on ITM-11 went longer without their cancer getting worse, compared to those on the alternative treatment.
That's a win. That's the kind of data companies spend hundreds of millions of dollars and years of work hoping to produce. ITM also has a second Phase 3 trial, called COMPOSE, running in a broader group of GEP-NET patients. By every clinical measure, ITM-11 looked like a drug heading toward approval.
Then the CRL landed.
The Kitchen Passed the Taste Test, But Failed the Health Inspection
Think of it like a restaurant. The food is delicious. Diners love it. Critics rave. But the health inspector walks in, checks the kitchen, and shuts the place down because the refrigeration units aren't up to code and a third-party supplier can't prove the ingredients were stored properly.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
That's essentially what the FDA told ITM. The agency flagged problems with Chemistry, Manufacturing, and Controls (CMC), which is the regulatory framework covering how a drug is made, tested, and quality-checked. The FDA also cited issues related to third-party commercial facilities, meaning some of the manufacturing sites ITM relies on didn't pass muster during inspection.
Critically, the CRL did not identify concerns about the clinical or nonclinical data. It did not flag safety problems. The science was fine. The manufacturing wasn't.
ITM hasn't disclosed the specific deficiencies, and the FDA's detailed inspection findings aren't publicly available yet. But the company has said it's reviewing the feedback and intends to resubmit after addressing the issues.
Why Making Radioactive Drugs Is Absurdly Hard
To understand why this happened, you need to appreciate just how nightmarish it is to manufacture a radiopharmaceutical. These aren't pills you press in a factory and ship in bottles. They're radioactive compounds that start decaying the moment they're made.
Picture trying to bake a cake that starts dissolving the second it comes out of the oven. You have to mix, bake, test, package, and deliver it before it's gone. That's the reality with lutetium-177, which has a half-life of about 6.6 days. Every step, from synthesis to purification to quality control to shipping, has to fit within a brutally tight window.
The challenges stack up fast. Quality control tests that might take days for a normal drug need to happen in hours. Manufacturing facilities require shielded hot cells (essentially lead-lined boxes with robotic arms) to protect workers from radiation. The supply of medical isotopes comes from a small number of specialized reactors and facilities worldwide, creating a fragile supply chain.
And here's what makes the regulatory piece especially tricky: standard drug-manufacturing templates simply don't translate well to radioactive products. The FDA still expects proof that your process is controlled, reproducible, and safe, but the usual playbook for demonstrating that doesn't account for a product that's literally disappearing while you test it.
A Pattern, Not a Fluke
ITM's rejection isn't an isolated incident. It reflects a systemic bottleneck across the booming radiopharmaceutical sector.
When the FDA published more than 200 redacted CRLs in 2025 covering applications from 2020 to 2024, independent analyses found a striking pattern: 74% of those letters involved quality or manufacturing problems. Not efficacy failures. Not safety scares. Factory floors, inspection findings, and CMC documentation gaps.
The radiopharmaceutical industry is experiencing a gold rush right now. More companies are developing radioactive cancer therapies than ever before. But the manufacturing infrastructure hasn't kept pace. More products are chasing the same scarce isotope supply, the same specialized facilities, and the same limited pool of expertise. It's a classic case of demand outrunning capacity.
Novartis knows this pain intimately. Its blockbuster radioligand therapy Pluvicto has faced well-documented supply constraints rooted in manufacturing and supply-chain complexity, not a lack of demand. When your product requires specialized radioactive-material handling at every step, scaling from clinical trials to commercial supply is enormously difficult. Geography matters because shipping time eats into your half-life. Facility capacity matters because you can't just rent extra space at a generic contract manufacturer.
The Competitive Angle
ITM-11 was positioning itself as a direct competitor to Novartis' Lutathera, which is already approved for GEP-NET patients. A delayed ITM-11 launch temporarily relieves competitive pressure on Novartis in this space. For GEP-NET patients who might have benefited from another treatment option, that's a real loss (even if hopefully a temporary one).
ITM isn't a scrappy startup, though. The company, founded in 2004 near Munich, is vertically integrated, meaning it controls isotope production, manufacturing, and clinical development under one roof. It recently announced operational readiness for its NOVA Facility, described as the world's largest lutetium-177 production site. ITM has built its entire business model around solving the very supply-chain problems that just tripped it up.
The irony is thick. A company that sells itself on manufacturing expertise got rejected for manufacturing issues. To be fair, the CRL specifically pointed to third-party facilities, suggesting the problem may lie with external partners rather than ITM's own operations. But that distinction offers limited comfort; regulators don't care whose name is on the factory door. If your supply chain has a weak link, the whole application suffers.
What Happens Next
ITM has said it plans to address the FDA's concerns and resubmit. The key question now is how long that takes. Some CMC-related CRLs get resolved in months with targeted fixes and a resubmission. Others, particularly those involving facility upgrades or new inspections, can drag on for a year or more.
For investors watching ITM (the company is privately held, so there's no public stock to track in real time), the calculus is relatively straightforward. The clinical data remains strong. The market opportunity in GEP-NETs is real. But revenue expectations just got pushed out by however long the resubmission process takes, and that delay has a cost.
For the broader radiopharmaceutical sector, ITM's CRL is a cautionary tale with a clear moral: clinical success is necessary but not sufficient. You can run a perfect Phase 3 trial, generate beautiful survival data, and still get stopped at the finish line by a manufacturing inspection.
The Bigger Picture
Radiopharmaceuticals represent one of the most exciting frontiers in oncology. The idea of attaching a radioactive payload to a molecule that seeks out cancer cells, delivering targeted radiation directly to tumors while sparing healthy tissue, is genuinely revolutionary. The sector is attracting billions in investment, and the pipeline is growing rapidly.
But the industry has an infrastructure problem that no amount of clever science can paper over. Making these drugs is hard. Scaling production is harder. Getting every link in a global, radioactive, time-sensitive supply chain to meet FDA standards is hardest of all.
ITM-11's story isn't over. The drug works. The data proves it. The company has the resources and the stated intent to fix what's broken and try again. But this episode should be a wake-up call for every radiopharmaceutical developer racing toward the FDA with strong clinical results and fragile manufacturing plans.
The FDA doesn't just ask whether your drug can save lives. It asks whether you can make it right, every single time, at scale. And right now, for a growing number of radioactive cancer therapies, that second question is the harder one to answer.
Clinical & Regulatory
4 min read
When the FDA Commissioner Tries to Kill a Drug Himself
Reports claim FDA Commissioner Marty Makary personally tried to block KalVista's rare disease drug, an almost unprecedented intervention that raises uncomfortable questions about political influence at the agency. The drug got approved anyway, but the fallout is just beginning.
